Last reviewed · How we verify

Furosemide 20 Milligrams

Instituto de Investigación Sanitaria Aragón · Phase 3 active Small molecule

Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume.

Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.

At a glance

Generic nameFurosemide 20 Milligrams
Also known asfurosemide 500 milligrams, hydrochlorothiazide 25 milligrams
SponsorInstituto de Investigación Sanitaria Aragón
Drug classLoop diuretic
TargetNa-K-2Cl cotransporter (NKCC2)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases urine output and reduces total body fluid volume, lowering blood pressure and reducing edema. It is one of the most potent diuretics available.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: